Established risk factors for venous thromboembolism (VTE) include: Obesity (BMI 30 kg/m), which increases venous stasis and pro-inflammatory states Immobility or reduced mobility , particularly relevant in patients with severe obesity Previous history of VTE or family history of thrombophilia Active malignancy or recent surgery Hormonal therapies , including combined oral contraceptives or hormone replacement therapy Pregnancy and the postpartum period Smoking , which affects endothelial function and coagulation Risk factors for arterial thrombosis (myocardial infarction, stroke) include: Type 2 diabetes mellitus , associated with endothelial dysfunction, platelet hyperreactivity, and a prothrombotic state Hypertension , causing arterial wall damage Dyslipidaemia , promoting atherosclerotic plaque formation Established cardiovascular disease Chronic kidney disease , common in diabetes and associated with increased cardiovascular risk Patients initiating GLP-1 therapy should undergo a comprehensive cardiovascular risk assessment

While both CVO and the hypothalamus are important, the hypothalamus is likely more central to the direct regulation of appetite and satiety through GLP-1 signaling
How to Restore Energy While on GLP-1 Medications Fortunately, several practical approaches can help combat fatigue while you continue to benefit from your GLP-1 medication
Los efectos secundarios ms comunes de Wegovy pueden incluir: nuseas, diarrea, vmitos, estreimiento, dolor de estmago (abdomen), dolor de cabeza, cansancio (fatiga), malestar estomacal, mareos, sensacin de hinchazn, eructos, niveles bajos de azcar en sangre en personas con diabetes tipo 2, gases, gastroenteritis, acidez de estmago y secrecin nasal o dolor de garganta